Target intelligence / Profile preview

Tumor suppressor candidate 8 (TUSC8)

Target
TUSC8
Molecular classification
Long non-coding RNA (lncRNA), Other (non-protein coding gene)
01

Overview

TUSC8 is a long non-coding RNA identified as a tumor suppressor candidate and is significantly down-regulated in a range of human cancers, including breast cancer, osteosarcoma, and cervical cancer. It mediates anti-tumor effects predominantly by acting as a competitive endogenous RNA that binds and sequesters oncogenic microRNAs, thereby promoting the expression of a range of tumor suppressor proteins (such as MYLIP, EHD2, and PTEN). The reduction of TUSC8 expression is associated with increased tumor cell proliferation, migration, invasion, and EMT, as well as poorer clinical outcomes. While TUSC8 itself is not a typical druggable target, it is studied as a prognostic biomarker and as a potential indirect therapeutic target through modulation of its regulatory axis in cancer signaling.

Other names
LINC01071XLOC_010588Tumor suppressor candidate 8
02

Mechanism of action

Not applicable for drugs, as TUSC8 is not a direct pharmacological target. Functionally, it acts by sequestering oncogenic microRNAs, thereby regulating expression of tumor suppressors or oncogenes (e.g., MYLIP, EHD2, PTEN, MDM2)

03

Biological functions

Regulation of cell proliferationInhibition of cell migration and invasionPromotion of apoptosisRegulation of epithelial-mesenchymal transition (EMT)Acting as a competitive endogenous RNA (ceRNA) that sponges oncogenic microRNAs (e.g., miR-190b-5p, miR-197-3p, miR-641)
04

Disease associations

Cancer (notably breast cancer, osteosarcoma, cervical cancer, and lung cancer)Tumor suppression
05

Safety considerations

None documented for direct targeting, as no therapeutics are available; manipulation of lncRNAs for therapy carries uncharacterized risks (e.g., off-target gene regulation, immune responses), but no specific safety data are available for TUSC8-based interventions.
06

Biomarkers

Expression level of TUSC8 (lower levels associated with poor prognosis in several cancers, higher levels predictive of better outcomes)Combined biomarker panels (TUSC8 + MYLIP in breast cancer)

Beyond the preview

Go deeper on Tumor suppressor candidate 8 (TUSC8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor suppressor candidate 8 (TUSC8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call